PMID- 35833358
OWN - NLM
STAT- MEDLINE
DCOM- 20220913
LR  - 20221015
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 22
IP  - 9
DP  - 2022 Sep
TI  - Efficacy and safety of multi-kinase inhibitors in patients with 
      radioiodine-refractory differentiated thyroid cancer: a systematic review and 
      meta-analysis of clinical trials.
PG  - 999-1008
LID - 10.1080/14737140.2022.2102000 [doi]
AB  - OBJECTIVES: Radioiodine-refractory differentiated thyroid cancer (RAI-rDTC) has 
      frequently been associated with poor prognosis. We conducted a meta-analysis of 
      published randomized controlled trials to evaluate multi-kinase inhibitors' 
      efficacy and safety profile treatment. METHODS: A comprehensive search was 
      conducted using PubMed, Embase, Cochrane, and Medline databases. The quality of 
      literature and trial risk of bias was assessed using the Cochrane risk of bias 
      tool, while the results of progression-free survival (PFS), overall survival 
      (OS), and adverse events (AEs) were evaluated using RevMan5.3 software. RESULTS: 
      Treatment with MKIs significantly improved PFS and OS, but AEs were significantly 
      higher than those in the control group (P < 0.01). The studies demonstrated the 
      median PFS (HR 0.30, 95% CI: 0.18-0.50, P < 0.00001) and OS (HR 0.70, 95% CI: 
      0.57-0.88, P = 0.002) in RAI-rDTC patients treated with MKIs, and the median PFS 
      of papillary thyroid carcinoma (HR0.28, 95% CI: 0.22-0.37, P < 0.00001) along 
      with follicular thyroid carcinoma (HR0.14, 95%CI 0.09-0.24, P < 0.00001) were 
      extended. CONCLUSION: MKIs significantly prolonged PFS and OS in patients with 
      RAI-rDTC (P < 0.01). Our recommendation is to use MKIs carefully in patients 
      after evaluating their health status to maximize treatment benefits and minimize 
      adverse effects.
FAU - Su, Jingyang
AU  - Su J
AUID- ORCID: 0000-0001-5592-7055
AD  - Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese 
      Medical University, Hangzhou, Zhejiang province, China.
FAU - Wang, Menglei
AU  - Wang M
AD  - Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese 
      Medical University, Hangzhou, Zhejiang province, China.
FAU - Fu, Yue
AU  - Fu Y
AD  - Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese 
      Medical University, Hangzhou, Zhejiang province, China.
FAU - Yan, Jiang
AU  - Yan J
AD  - Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese 
      Medical University, Hangzhou, Zhejiang province, China.
FAU - Shen, Yuezhong
AU  - Shen Y
AD  - Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese 
      Medical University, Hangzhou, Zhejiang province, China.
FAU - Jiang, Jing
AU  - Jiang J
AD  - Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese 
      Medical University, Hangzhou, Zhejiang province, China.
FAU - Wang, Jue
AU  - Wang J
AD  - Department of Oncology, Hangzhou Hospital of Traditional Chinese Medicine 
      Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang province, 
      China.
FAU - Lu, Jinhua
AU  - Lu J
AD  - Department of Oncology, Hangzhou Hospital of Traditional Chinese Medicine 
      Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang province, 
      China.
FAU - Zhong, Yazhen
AU  - Zhong Y
AD  - Department of Oncology, Hangzhou Hospital of Traditional Chinese Medicine 
      Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang province, 
      China.
FAU - Lin, Xianlei
AU  - Lin X
AD  - Department of Oncology, Hangzhou Hospital of Traditional Chinese Medicine 
      Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang province, 
      China.
FAU - Lin, Zechen
AU  - Lin Z
AD  - Department of Oncology, Hangzhou Hospital of Traditional Chinese Medicine 
      Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang province, 
      China.
FAU - Lin, Shengyou
AU  - Lin S
AUID- ORCID: 0000-0001-6798-0945
AD  - Department of Oncology, Hangzhou Hospital of Traditional Chinese Medicine 
      Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang province, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20220720
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Iodine Radioisotopes)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects
MH  - Humans
MH  - Iodine Radioisotopes/adverse effects
MH  - Progression-Free Survival
MH  - *Thyroid Neoplasms/drug therapy
OTO - NOTNLM
OT  - Meta-analysis
OT  - Multi-kinase inhibitors
OT  - Radioiodine-refractory differentiated thyroid cancer
OT  - adverse events
OT  - efficacy
OT  - systematic review
EDAT- 2022/07/15 06:00
MHDA- 2022/09/14 06:00
CRDT- 2022/07/14 04:33
PHST- 2022/07/15 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
PHST- 2022/07/14 04:33 [entrez]
AID - 10.1080/14737140.2022.2102000 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2022 Sep;22(9):999-1008. doi: 
      10.1080/14737140.2022.2102000. Epub 2022 Jul 20.